Bortezomib: Putting mantle cell lymphoma on death row

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 657-658

  Wei, Andrew H ^a   Roberts, Andrew W ^b,c  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; BORTEZOMIB; CYCLIN D1; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLAVOPIRIDOL; MYC PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; TEMSIROLIMUS;

3' UNTRANSLATED REGION; APOPTOSIS; CANCER SURVIVAL; CELL CYCLE; CELL DAMAGE; CELL STRESS; CHROMOSOME TRANSLOCATION; CYTOTOXICITY; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; MANTLE CELL LYMPHOMA; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS REGULATORY PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BORONIC ACIDS; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEASE INHIBITORS; PYRAZINES;

EID: 42049112840     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801942378     Document Type: Note

References (10)

1. Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M. and Corato, A. (2000) Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95, p. 619-626.
2. Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F. and Nakayama, K. (2007) Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood, 109, p. 4599-4606.
3. Rizzatti, E. G., Mora-Jensen, H., Weniger, M. A., Gibellini, F., Lee, E. and Daibata, M. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-κB pathways. Leuk Lymphoma 2008;49:798-808
4. Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X. and Ota, A. (2005) Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene, 24, pp. 1348-1358.
5. Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I. and Hinds, M. G. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell, 17, pp. 393-403.
6. Perez-Galan, P., Roue, G., Villamor, N., Montserrat, E., Campo, E. and Colomer, D. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 107, pp. 257-264.
7. Willis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E. and Fletcher, J. I. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev, 19, pp. 1294-1305.
8. Nikrad, M., Johnson, T., Puthalalath, H., Coultas, L., Adams, J. and Kraft, A. S. (2005) The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Therapeutics, 4, pp. 443-449.
9. Certo, M., Moore, V DG, Nishino, M., Wei, G., Korsmeyer, S. and Armstrong, S. A. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell, 9, pp. 351-365.
10. Nikiforov, M. A., Tang, W. H., Gratchouck, V., Zhuang, D., Fernandez, Y. and Verhaegen, M. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA, 104, pp. 19488-19493.